FDA eases rules to head off shortage of IV nutrition for premature newborns

The Food and Drug Administration said Friday it is loosening manufacturing rules for a narrow category of intravenous nutrition used to keep the sickest and most premature newborns alive, after hospital pharmacists warned that two compounding plants making the product were shutting down for good.

The agency's announcement on Friday covers what is known clinically as "starter" parenteral nutrition, a premixed intravenous solution of amino acids, sugar, electrolytes and fluid that neonatal intensive care units keep on hand to feed infants within hours of birth, before a pharmacist can compound a formula tailored to that baby's bloodwork. Babies born many weeks early, or too sick to tolerate milk, often cannot eat by mouth or feeding tube and depend entirely on such intravenous nutrition to survive their first days.

What the FDA is changing

The FDA said it learned of a potential supply gap after children's hospitals raised concerns about continued access to standardized neonatal starter formulas once two outsourcing facilities that made them close permanently. Outsourcing facilities are pharmacy-like manufacturers registered with the FDA that supply hospitals with compounded drugs in bulk, without a prescription tied to a specific patient, under more manufacturing oversight than an ordinary pharmacy.

In response, the agency issued an immediately effective guidance document telling both outsourcing facilities and ordinary state-licensed and hospital pharmacies that it does not intend to take enforcement action if they compound and distribute starter parenteral nutrition for newborns without meeting certain standard requirements — among them, the usual rule that a compounded drug be tied to an individual patient's prescription rather than shipped to a hospital in bulk. The policy also sets default shelf-life periods pharmacies can use in place of the stability testing normally required before a compounded drug can be labeled with an expiration date. A copy of the guidance was also logged with the Federal Register's public inspection desk on Friday, formalizing its effective date. The FDA described the policy as temporary, to remain in place only while the supply gap persists.

A supply chain with little slack

Starter parenteral nutrition is not, by itself, a new addition to the FDA's list of drugs in short supply. The agency's own drug shortage database currently lists intravenous amino acid injection — the core protein component of parenteral nutrition — as an active shortage, alongside several concentrations of dextrose injection, the sugar solution mixed into the same bags. Both are inputs that hospital and outsourcing pharmacies need on hand before they can compound a finished nutrition product for a neonatal unit, so a shortfall in either ingredient compounds the effect of losing two finished-product suppliers at once.

The vulnerability is not new. Nutrition support pharmacists have logged shortages of parenteral nutrition components — amino acids, multivitamins, trace elements, sterile water — for more than a decade, a pattern the American Society for Parenteral and Enteral Nutrition tracks on a running clinical resource page it updates as products go in and out of stock. Premature infants are considered especially exposed to these gaps because, unlike an older patient who can eat around a shortage, an extremely low-birth-weight newborn typically has no other route to adequate nutrition for its first one to several weeks of life. A peer-reviewed analysis published in the journal Nutrients examining earlier parenteral nutrition shortages found that rationed micronutrients in these solutions have been linked to complications including metabolic bone disease and vitamin deficiencies in hospitalized infants, underscoring why clinicians treat even brief interruptions in supply as a patient-safety concern rather than a paperwork problem. The FDA has used similar emergency compounding flexibility before: in October 2024, it issued comparable temporary policies for a broader set of intravenous fluids after a hurricane disabled a major manufacturing plant that supplied much of the country's sterile IV solutions, forcing hospitals nationwide to ration bags of saline and dextrose for weeks.

Who is affected, and what officials are saying

The policy is aimed squarely at hospital pharmacies and neonatal intensive care units, which are the primary customers for standardized starter parenteral nutrition, rather than at consumers directly. Children's hospitals and academic medical centers with large NICUs are typically the heaviest users of premixed starter formulas, since they can keep the product stocked and ready rather than compounding a custom bag for every admission in real time overnight. Community hospitals with smaller newborn units, which often rely on outside compounding pharmacies precisely because they lack the staff to compound sterile nutrition solutions in-house, are also exposed if their suppliers cannot fill orders.

"The FDA is committed to deploying every regulatory tool available to prevent critical supply chain gaps from threatening patient care," Acting FDA Commissioner Kyle Diamantas said in the announcement.

Michael Davis, the acting director of the FDA's drug evaluation center, said the temporary rules were meant as a bridge rather than a permanent fix, noting that they are "intended to help hospitals maintain access to this life-saving nutrition during this transition." The agency did not name the two outsourcing facilities that are closing, nor did it disclose how many hospitals had reported difficulty securing supply, saying only that it intends to monitor the situation and adjust the policy, including which specific products it covers, as conditions change.

What happens next

The guidance takes effect immediately and carries no fixed expiration date; the FDA said it will remain in force only for the duration of the supply disruption, and that it plans to update, narrow or withdraw the policy as the market stabilizes. In practice, that means hospital and outsourcing pharmacies now have a defined path to keep producing and shipping starter parenteral nutrition for newborns under relaxed prescription and shelf-life rules, provided the specific products they compound match a list the FDA is posting and periodically updating on its website. The agency is also urging doctors and pharmacists to report any adverse events tied to compounded nutrition products through its MedWatch reporting system, a signal that it is trying to monitor quality even as it eases the rules that would normally apply. Whether the underlying shortage resolves quickly will depend largely on how fast alternative manufacturers, or the two departing outsourcing facilities' competitors, can scale up production of a sterile product that by its nature cannot be stockpiled for long before it expires.